You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Dec 17, 2025

High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
Sean Lin1, Kenji Schorpp1, Ina Rothenaigner1
1Assay Development and Screening Platform, Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum München, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany.
Phenotypic drug discovery (PDD) uses cell imaging to find new drugs. Advances in image analysis and machine learning make high-content screening (HCS) a powerful tool for drug discovery, despite data challenges.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: